The FDA is questioning the safety and effectiveness of Pfizer's (PFE) proposed tofacitinib drug for rheumatoid arthritis, saying it appears to reduce swollen and tender joints during clinical trials but questioning the method of analyzing X-rays to prove the drug worked. The product will be reviewed Wednesday by the FDA’s arthritis drugs advisory committee. PFE -0.6% premarket
Market Data 
Markets 
AI
